EN DE
Watch Jiangsu Lianhuan Pharmaceutical Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Jiangsu Lianhuan Pharmaceutical Co Ltd stock ¥5.89, price ¥12.86, that is 54.2% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE000001DP6

JL Jiangsu Lianhuan Pharmaceutical Co Ltd logo Thin data Nov 5, 2026

Jiangsu Lianhuan Pharmaceutical Co Ltd

600513 · SHG
Very expensive, weak quality

Our calculation puts a fair price 54% below what the stock costs today.

Low debt
Revenue last quarter +16% vs. a year ago.
Mixed Growth (revenue 5y +10.9 %/yr in CNY)
Loss over the last twelve months · -1.6% net margin (TTM) · fiscal year 2024 3.9%
0.5% dividend yield · Token dividend
Fair value ¥5.89 · Strongly overvalued (−54.2%)
Quality 37/100
Negative free cash flow
Trails peers (3/12)
Narrow moat 21/100 · thin data
Thin data
Watch Jiangsu Lianhuan Pharmaceutical Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥30.75 ¥7.14 Fair Value ¥5.89 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range ¥7.14 – ¥30.75 · fair‑value band ¥4.03 – ¥7.75 · the ¥12.86 price screens above the ¥5.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.

Follow Jiangsu Lianhuan Pharmaceutical Co in your weekly email

Every Wednesday you see whether Jiangsu Lianhuan Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally.

Show moreShow less

The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, milrinone, dapoxetine hydrochloride, tadalafil, and betasine besylate tablets, as well as aprilite, danazol suppositories, and terfenadine tablets.

It also provides urinary system drugs, including eprepitant tablets, terazosin tablets, and drotaverine hydrochloride injections; antihistamines comprising ebastine, terfenadine, and cetirizine hydrochloride tablets; cardiovascular drugs that include felodipine, simvastatin, and amlodipine maleate tablets; steroid hormones, which consist of prazosinone sulfate sodium for injection and danazol capsules; and antibiotics, such as oxithromycin capsules.

In addition, the company offers API products, such as hydrocortisone, hydrocortisone acetate, levonorgestrel, dexamethasone sodium phosphate, dexamethasone acetate, tazarotene, saxagliptin monohydrate, sacubitril valsartan sodium, phentolamine mesylate, terfenadine, aminomethylbenzoic acid, drotaverine hydrochloride, felodipine, ebastine, lumbrokinase, chloramphenicol, balofoxacin, fludrocortisone acetate, relugolix, hydrocortisone valerate, and bilastine.

Further, it engages in the wholesale of chemical raw materials and pharmaceuticals, as well as the sale of medical equipment and electronic products. The company exports its products. Jiangsu Lianhuan Pharmaceutical Co., Ltd. was founded in 1999 and is based in Yangzhou, China.

Stock analysis

Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) currently trades at ¥12.86, while our model-based Fair Value estimate is ¥5.89, 54% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ¥6.34 per share, and 0 of the 16 models we run sit above the ¥12.86 price.

Bear case: the Asset-Based group reads lowest at ¥0.6200, and 16 of the 16 models stay below the price. Data coverage for this calculation is low.

Scenario range: ¥4.03 (bear) to ¥7.75 (bull), the price of ¥12.86 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Jiangsu Lianhuan Pharmaceutical Co Ltd reported revenue of 2.2B CNY in FY2024 versus 1.4B CNY in FY2020, a compound +11.7%/yr. Reported net income was 84.2M CNY in FY2024, compounding −4.9%/yr from FY2020.

Key figures

Market cap 3.9B CNY (≈ $588M) Small · P/S ratio 1.27 · EPS (TTM) ¥−0.1600 · Dividend yield 0.5% · Net margin −1.6% · Return on equity −2.2% · Return on assets (EBIT) 6.2% (5-year average) · Operating margin 2.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).

What moves the price

The share trades about 58% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −54%, 600513 screens richer than that median.

Fair Value models

Bear ¥4.03 Fair Value ¥5.89 Bull ¥7.75
Price ¥12.86 · Downside -54.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ¥3.55 ¥3.56 ¥3.75 76
EPV ¥2.62 ¥2.90 ¥3.13 73
ROIC Compounder ¥2.62 ¥2.90 ¥3.13 71
All 16 models by family
Earnings-Based
Graham-Dodd ¥2.00 ¥10.63 ¥14.72 63
Lynch FV ¥2.93 ¥4.18 ¥5.44 61
PEG = 1.0 ¥2.93 ¥4.18 ¥5.44 57
EPV ¥2.62 ¥2.90 ¥3.13 73
Dividend Discount
Gordon GGM ¥1.02 ¥1.75 ¥2.32 68
DDM Multi-Stage ¥1.02 ¥1.64 ¥1.88 67
Multiples
P/E Multiple ¥4.86 ¥6.49 ¥8.11 63
P/S Multiple ¥3.76 ¥5.01 ¥6.27 57
P/B Multiple ¥8.44 ¥11.26 ¥14.07 55
EV/EBIT ¥3.09 ¥4.63 ¥6.17 64
EV/EBITDA ¥4.03 ¥5.89 ¥7.75 66
EV/Revenue ¥1.76 ¥3.18 ¥4.59 51
Asset-Based
NCAV (Graham) ¥0.4100 ¥0.6200 ¥0.7700 54
Economic Profit
Residual Income ¥3.55 ¥3.56 ¥3.75 76
ROIC Compounder ¥2.62 ¥2.90 ¥3.13 71
Growth Earnings
Growth-Adj P/E ¥4.44 ¥6.34 ¥8.25 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 41
How much profit the company makes from its sales and capital
Quality Growth 33
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 58
Debt, balance sheet and risk of trouble
Investment 63
Does it invest with discipline instead of growing at any price?
Low Volatility 52
How calm the share price moves, does not count
Price momentum 11
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 47
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 37/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.9%
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.7%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+5.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+4.8%
Dividend (yield on the price)0.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.0.7% vs 5.8%, slowing
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 6%

600513 screens overvalued: fair value 54% below the price. Compare with Merck KGaA →

Compare Jiangsu Lianhuan Pharmaceutical Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 3/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −54.2% · Below median
Profitability
Return on assets 3.5% · Below median
Net margin (12 months) −2.0% · Bottom 25%
Operating margin (12 months) 2.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) 15.6% · Above median
Dividend yield (12 months) 0.5% · Bottom 25%
Balance sheet
Debt / equity 0.06× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 2.81× · Pricier than median
P/S (12 months) 1.65× · Cheaper than median
EV/EBITDA 47.1× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)78 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)97 · sector 96
DIVIDEND (yield)11 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $111.63 +41% vs 600513
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs 600513
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs 600513
Haleon plc HLN $9.14 $8.61 −6% vs 600513
Merck KGaA MRK €148.75 €109.18 −27% vs 600513
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs 600513
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs 600513
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 600513
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs 600513
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs 600513

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jiangsu Lianhuan Pharmaceutical Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Jiangsu Lianhuan Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/600513

Frequently asked questions

Is Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ¥5.89 versus a price of ¥12.86, about 54% lower (overvalued).
What is the fair value of 600513?
Our model-based fair value for Jiangsu Lianhuan Pharmaceutical Co Ltd is ¥5.89 (as of Nov 5, 2026), built from audited fundamentals. The current price: ¥12.86.
What is the quality score of 600513?
Jiangsu Lianhuan Pharmaceutical Co Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
Our model-based price target is the fair value of ¥5.89 (as of Nov 5, 2026) from 16 valuation models. Cautious scenario ¥4.03, optimistic scenario ¥7.75. It is a calculation from audited fundamentals, not an analyst target.
What is the Jiangsu Lianhuan Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at ¥5.89, about 54% lower versus a price of ¥12.86 (overvalued). Cautious scenario ¥4.03, optimistic scenario ¥7.75. The calculation is refreshed regularly with new filings.
What is the revenue of Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
Jiangsu Lianhuan Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 3.0B CNY (latest available figure, as of Nov 5, 2026).
Does Jiangsu Lianhuan Pharmaceutical Co Ltd pay a dividend?
Jiangsu Lianhuan Pharmaceutical Co Ltd currently shows a dividend yield of 0.54% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) and when is the ex-dividend date?
Jiangsu Lianhuan Pharmaceutical Co Ltd pays a dividend of ¥0.07 per share a year, a dividend yield of 0.5%. The last ex-dividend date was Jul 8, 2026. The payout ratio is 23.7% of earnings. Our assessment: Token dividend. At a yield of 0.5% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.5% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jiangsu Lianhuan Pharmaceutical Co Ltd it is ¥5.89 per share (as of Nov 5, 2026), against a price of ¥12.86. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Jiangsu Lianhuan Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 600513 trades above its calculated fair value: price ¥12.86, fair value ¥5.89, a gap of about −54% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 600513?
No. The price is what the market pays today (¥12.86); the fair value is what the company's own numbers justify (¥5.89). For Jiangsu Lianhuan Pharmaceutical Co Ltd the two are ¥6.97 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jiangsu Lianhuan Pharmaceutical Co Ltd worth?
The market values Jiangsu Lianhuan Pharmaceutical Co Ltd at about 3.9B CNY (market capitalisation, as of Nov 5, 2026). Per share that is ¥12.86; our models calculate a fair value of ¥5.89 per share.
What do the bullish and bearish scenarios say about 600513?
Our models span a range for Jiangsu Lianhuan Pharmaceutical Co Ltd: cautious scenario ¥4.03, base ¥5.89, optimistic ¥7.75 per share (as of Nov 5, 2026, price ¥12.86). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
Balance-sheet figures for Jiangsu Lianhuan Pharmaceutical Co Ltd (as of Nov 5, 2026): return on equity −2.2%, debt of 0.06 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 600513 from its 52-week high?
Jiangsu Lianhuan Pharmaceutical Co Ltd trades at ¥12.86, about 58% below its 52-week high of ¥30.75 and 3% above the low of ¥12.47 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥5.89 is for.
Which stocks are comparable to Jiangsu Lianhuan Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jiangsu Lianhuan Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price ¥12.86, calculated fair value ¥5.89 (−54%), Quality Score 37/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 600513 calculated?
We run Jiangsu Lianhuan Pharmaceutical Co Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥5.89 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Jiangsu Lianhuan Pharmaceutical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
The closing price on Nov 6, 2026 was ¥12.86. Our model-based fair value is ¥5.89, about 54% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jiangsu Lianhuan Pharmaceutical Co Ltd right now?
The price sits above even our optimistic bull case (¥7.75). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥4.03 to ¥7.75) leaves room in how you read the outcome.
Where does the earnings growth of Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) come from?
Earnings per share at Jiangsu Lianhuan Pharmaceutical Co Ltd grew +11.1 % a year from 2013 to 2024. Broken into its drivers: revenue per share +13.3 %, EBIT margin −0.5 %, tax rate +0.1 %, residual (interest, one-offs) −1.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Jiangsu Lianhuan Pharmaceutical Co Ltd

How large is the market capitalisation of Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
The market capitalisation of Jiangsu Lianhuan Pharmaceutical Co Ltd is 3.9B CNY (≈ $588M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
The price-to-sales ratio of Jiangsu Lianhuan Pharmaceutical Co Ltd is 1.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
Earnings per share at Jiangsu Lianhuan Pharmaceutical Co Ltd are ¥−0.1600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
The dividend yield of Jiangsu Lianhuan Pharmaceutical Co Ltd is 0.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
The net margin of Jiangsu Lianhuan Pharmaceutical Co Ltd is −1.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
The return on equity (ROE) of Jiangsu Lianhuan Pharmaceutical Co Ltd is −2.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
On an EBIT basis the return on assets of Jiangsu Lianhuan Pharmaceutical Co Ltd is 6.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
The operating margin of Jiangsu Lianhuan Pharmaceutical Co Ltd is 2.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
Revenue at Jiangsu Lianhuan Pharmaceutical Co Ltd is growing +15.6% versus a year earlier (3y avg +9.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)?
Earnings per share at Jiangsu Lianhuan Pharmaceutical Co Ltd are growing −75.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) generate?
The free cash flow of Jiangsu Lianhuan Pharmaceutical Co Ltd is −174M CNY (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) carry?
The net debt of Jiangsu Lianhuan Pharmaceutical Co Ltd is 556M CNY (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Jiangsu Lianhuan Pharmaceutical Co Ltd in the live analysis

One click puts Jiangsu Lianhuan Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.